Amazon Continues Investments in Renewable Energy – Announces Two New Renewable Energy Projects in U.S. and EU; Now Has 66 Projects Globally, Including 51 Solar Rooftops
1.8.2019 13:00:00 EEST | Business Wire | Press release
Amazon (NASDAQ: AMZN) today announced the company’s 65th and 66th renewable energy projects. Amazon’s newest renewable energy project in the EU will be located in Cork, Ireland, and will be the second Amazon Wind Farm in the Republic of Ireland. Once complete, the new Amazon Wind Farm will provide 23.2 megawatts (MW) of renewable capacity, with expected generation of 68,000 megawatt hours (MWh) of clean energy annually. Amazon’s newest renewable energy project in the U.S. will be located in Pittsylvania County, Virginia, and will be the seventh Amazon Solar Farm in the Commonwealth of Virginia. Once complete, the new Amazon Solar Farm will provide 45 megawatts (MW) of renewable capacity and is expected to generate 100,000 megawatt hours (MWh) of clean energy annually. Both projects are expected to begin producing clean energy in 2020 and will supply clean energy to the company’s Amazon Web Services datacenters, which power Amazon and millions of AWS customers globally.
Additionally, Amazon’s investments in renewable energy were recently recognized in the Solar Energy Industries Association’s (SEIA) 2018 Solar Means Business Report, which ranked Amazon #1 in the U.S. for amount of corporate on-site solar installed in 2018, and #2 for total amount of solar installed to date. Amazon’s solar projects in the U.S. have offset the CO2 equivalent of more than 200 million miles of truck deliveries. Globally, Amazon has 66 renewable energy projects – including 51 solar rooftops – that are expected to generate 1,342 MW of renewable capacity and deliver more than 3.9 million MWh of clean energy annually.
“Playing a significant role in helping to reduce the sources of human-induced climate change is an important commitment for Amazon,” said Kara Hurst, Director of Sustainability, Amazon. “Major investments in renewable energy are a critical step to address our carbon footprint globally. We will continue to invest in these projects, and look forward to additional investments this year and beyond.”
“Under the Climate Action Plan, we are committing that 70 percent of Ireland’s electricity will come from renewable sources by 2030. Industry leadership is key to helping us reach this target,” said Richard Bruton, Ireland’s Minister for Communications, Climate Action and Environment. “This project is another example of AWS’s commitment to renewable projects in Ireland, adding clean energy to the grid, and supporting Ireland’s climate commitments. Construction will begin on this project this year and will start contributing to Ireland’s renewable energy capacity by 2020. We look forward to continuing to work with AWS as we strive to make Ireland a leader in the renewable energy space.”
“I applaud Amazon for their continued investment in clean and renewable energy projects in the Commonwealth of Virginia,” said Virginia Senator Mark R. Warner. “This solar energy project in Pittsylvania County will lead to a cleaner environment and more jobs in the community.”
“It’s wonderful to see the announcement of these new projects, which will help bring more renewable energy to the Commonwealth of Virginia where Amazon has already helped bring significant solar energy projects online,” said Virginia Governor Ralph Northam. “Amazon’s new solar farm in Virginia will create jobs and economic development in rural Virginia, and will continue to build upon our role as a leading state for renewable energy in the U.S.”
Beyond investments in wind and solar, Amazon has a long history of commitment to sustainability through innovative programs such as Shipment Zero, Frustration-Free Packaging, Ships in Own Container, investments in the circular economy with the Closed Loop Fund, and numerous other initiatives happening every day by teams across Amazon. Amazon has also implemented the District Energy Project that uses recycled energy to heat and cool more than 3 million square feet of office space. For more information on Amazon’s sustainability initiatives, visit www.amazon.com/sustainability.
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.
About Amazon Web Services
For 13 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud platform. AWS offers over 165 fully featured services for compute, storage, databases, networking, analytics, robotics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 66 Availability Zones (AZs) within 21 geographic regions, spanning the U.S., Australia, Brazil, Canada, China, France, Germany, Hong Kong Special Administrative Region, India, Ireland, Japan, Korea, Singapore, Sweden, and the UK. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190801005260/en/
Contact information
Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
